White Muscle Disease (cardiac form)

White muscle disease in its cardiac form represents a serious and often rapidly fatal manifestation of selenium and vitamin E deficiency that specifically damages heart muscle tissue, causing acute cardiac failure in young ruminants and other susceptible farm animals. This nutritional deficiency disease occurs when inadequate selenium and vitamin E intake fails to protect cell membranes from oxidative damage, allowing free radical injury to accumulate in metabolically active tissues including heart muscle. The cardiac form of white muscle disease is distinguished from the skeletal muscle form by its primary involvement of the myocardium and its typically more acute and severe clinical presentation with higher mortality rates.

White muscle disease primarily affects young ruminants including calves, lambs, and goat kids, with the cardiac form most commonly seen in neonates and young animals under three months of age born to dams that were selenium and vitamin E deficient during pregnancy. The condition occurs worldwide but is most prevalent in geographic regions where soil selenium content is low, resulting in selenium-deficient forages and grains that fail to meet animal requirements. Certain areas of North America, particularly the Pacific Northwest, Great Lakes region, and Atlantic seaboard, as well as parts of Europe, Australia, and New Zealand, are recognized as selenium-deficient areas with elevated white muscle disease incidence.

The economic and welfare impact of white muscle disease can be substantial in affected herds and flocks, with mortality rates reaching twenty to thirty percent or higher in severely deficient populations. The cardiac form carries a particularly grave prognosis, with affected animals often dying before treatment can be initiated. Beyond direct mortality losses, subclinical deficiency reduces growth rates, impairs immune function, and decreases reproductive performance. The condition is entirely preventable through appropriate selenium and vitamin E supplementation, making losses from white muscle disease particularly frustrating as they represent failure to provide adequate nutrition rather than unavoidable disease.

White muscle disease is highly responsive to prevention through selenium and vitamin E supplementation, and even clinical cases can respond dramatically to treatment if detected before severe myocardial damage occurs. However, the cardiac form often progresses rapidly, with sudden death occurring before clinical signs are recognized, limiting treatment opportunities. Understanding regional selenium status, recognizing risk factors, and implementing appropriate supplementation programs are essential for preventing this entirely avoidable condition. Regular monitoring of selenium status in at-risk populations allows adjustment of supplementation programs to maintain adequate protection.

The primary cause of white muscle disease is nutritional deficiency of selenium, vitamin E, or both nutrients, which function synergistically to protect cell membranes from oxidative damage. Selenium serves as an essential component of glutathione peroxidase enzymes that neutralize hydrogen peroxide and organic peroxides generated during normal cellular metabolism. Vitamin E functions as a fat-soluble antioxidant within cell membranes, scavenging free radicals and preventing lipid peroxidation. When both nutrients are deficient, antioxidant protection fails and metabolically active tissues with high oxygen consumption, particularly muscle and heart, accumulate oxidative damage that disrupts cell function and causes tissue degeneration.

Geographic and soil factors strongly influence selenium deficiency risk, as plants absorb selenium from soil and animals obtain selenium primarily through dietary plants. Selenium-deficient soils exist in many regions worldwide, often associated with high rainfall areas where selenium has been leached from surface soils, or areas where soil chemistry makes selenium unavailable for plant uptake. In selenium-deficient regions, all locally produced feeds including pasture, hay, and grain are likely to be deficient unless selenium fertilization has been applied. Animals consuming exclusively local feeds in deficient areas are at high risk unless supplementation is provided.

Environmental and management factors beyond soil selenium status influence white muscle disease risk. Vitamin E content of feeds decreases with storage and processing, particularly in hay that has been stored for extended periods or feeds that have become rancid. High-fat diets increase vitamin E requirements due to increased lipid peroxidation risk. Rapid growth rates and high metabolic demand increase antioxidant requirements. Stress from transport, handling, or disease increases oxidative stress and may precipitate clinical disease in marginally deficient animals. Young animals born to deficient dams have minimal selenium and vitamin E reserves and are immediately at risk.

Risk factors for white muscle disease include birth to dams on deficient diets, residence in selenium-deficient geographic regions, consumption of locally produced feeds without supplementation, high growth rates, and recent stress events. The perinatal period represents highest risk for the cardiac form, as neonates depend on colostral transfer of selenium and vitamin E from dams that may themselves be deficient. Young, rapidly growing animals have high metabolic rates and antioxidant demands. Lambs and kids are often at higher risk than calves due to their higher metabolic rate and faster growth relative to body size.

The pathophysiology of cardiac white muscle disease involves progressive oxidative damage to cardiomyocytes, leading to myofibrillar degeneration, membrane disruption, and cell death. The heart's continuous metabolic activity and high oxygen consumption make it particularly vulnerable to antioxidant deficiency. As cardiomyocytes degenerate, they are replaced by fibrous tissue and mineralization, creating the characteristic white streaks and patches visible on cut surfaces of affected hearts. The degenerative changes impair cardiac contractility and may disrupt electrical conduction, leading to arrhythmias, pump failure, and death. Unlike skeletal muscle, cardiac muscle has very limited regenerative capacity, making severe damage irreversible.

Early warning signs of cardiac white muscle disease may be subtle or absent, with many affected animals found dead without preceding clinical signs having been observed. In animals that do show prodromal signs, subtle exercise intolerance may be noted before acute collapse, with affected animals falling behind when groups are moved or showing labored breathing after minimal exertion. Depression and weakness may be observed in the hours or days before death. Because affected animals are typically neonates or young animals in group settings, individual observation may be limited and early signs easily missed among normally resting young stock.

As the cardiac form progresses, affected animals display rapidly worsening signs of heart failure. Sudden onset of respiratory distress with rapid, labored breathing reflects developing pulmonary edema from left-sided heart failure. Tachycardia with weak, thready pulses indicates failing cardiac output. Affected animals become increasingly depressed and reluctant to rise or move. Mucous membranes may appear pale or cyanotic as tissue oxygenation fails. Temperature may be subnormal in animals with circulatory collapse. The rapid progression of signs often leads to death within hours of onset.

Behavioral changes in animals with cardiac white muscle disease include profound weakness, depression, and recumbency. Affected animals may lie flat with extended limbs rather than maintaining normal resting postures. Attempts to stand may be unsuccessful or result in immediate collapse. Nursing or eating behavior ceases as animals become too weak and distressed to feed. Vocalizations may decrease or change character. Animals may show apparent distress including labored breathing and occasional groaning. Separation from dams in nursing animals occurs as weakness prevents following.

Physical signs of cardiac white muscle disease include the manifestations of acute heart failure combined with any concurrent skeletal muscle involvement. Auscultation may reveal tachycardia, arrhythmias, or abnormal heart sounds if the animal survives long enough for examination. Pulmonary crackles may be audible with pulmonary edema. Peripheral edema may be present but is often minimal due to the acute nature of cardiac failure. Muscle tremors, stiffness, or weakness from concurrent skeletal muscle disease may be present. Elevated respiratory rate and effort are nearly universal findings in animals with significant cardiac involvement.

Symptom progression in cardiac white muscle disease is typically rapid, with death occurring within hours to days of the first observed clinical signs. Some animals are simply found dead without any prior indication of illness, representing peracute cases where cardiac failure was so rapid that no premonitory signs occurred. In cases where progression is observed, initial depression and weakness advance quickly to recumbency, respiratory distress, and cardiovascular collapse. The combination of cardiac and skeletal muscle disease, when both are present, compounds weakness and respiratory compromise.

Emergency symptoms indicating imminent death include severe respiratory distress with gasping, complete recumbency with inability to lift the head, cold extremities indicating circulatory failure, loss of consciousness, and terminal arrhythmias that may be palpable as irregular or absent pulses. Animals in extremis have grave prognosis even with emergency treatment, as severe myocardial damage cannot be reversed. The decision between emergency treatment and humane euthanasia must be made quickly in animals with severe cardiac involvement.

Clinical diagnosis of cardiac white muscle disease is based on recognition of acute heart failure in young ruminants from herds or flocks at risk for selenium and vitamin E deficiency, combined with exclusion of other causes of sudden death and cardiac disease in this age group. History of inadequate supplementation, residence in selenium-deficient areas, or previous cases in the herd supports the diagnosis. The age of affected animals, with peak incidence in neonates through three months, fits the epidemiological profile of white muscle disease. Finding concurrent skeletal muscle disease in the same or other animals strengthens the diagnosis.

Diagnostic testing for white muscle disease incorporates both ante-mortem laboratory assessment and post-mortem pathological examination. Blood selenium levels and glutathione peroxidase activity provide objective measures of selenium status, with deficient animals showing low values. Serum vitamin E concentrations can be measured but are less commonly performed. Muscle enzymes including creatine kinase and aspartate aminotransferase are typically markedly elevated due to muscle cell damage. Cardiac troponin levels may be elevated indicating myocardial damage specifically. Response to selenium and vitamin E treatment provides presumptive diagnostic support if clinical improvement occurs.

Post-mortem examination provides definitive diagnosis of cardiac white muscle disease through characteristic gross and microscopic pathology. Affected hearts show pale white streaks and patches in the myocardium, particularly affecting the left ventricular wall and interventricular septum, representing areas of muscle degeneration and necrosis that gave the disease its common name. Pulmonary edema and hepatic congestion from heart failure are typically present. Microscopic examination reveals Zenker's degeneration of cardiac muscle fibers with hyalinization, fragmentation, and mineralization. Concurrent skeletal muscle lesions in tongue, intercostal, or limb muscles support the diagnosis.

Differential diagnosis for cardiac white muscle disease includes other causes of acute death and cardiac disease in young ruminants. Enterotoxemia from Clostridium perfringens causes peracute death but typically shows intestinal and other characteristic lesions. Septicemia from various bacterial causes may present similarly but usually shows evidence of infection at necropsy. Congenital heart defects cause cardiac failure but lack the characteristic white muscle pathology. Ionophore toxicity causes cardiac muscle damage but is associated with ionophore-containing feed consumption. Plant toxicities affecting the heart should be considered if animals had access to potentially toxic plants. Copper deficiency cardiomyopathy occurs in similar populations but has distinct pathology.

Emergency treatment of animals with acute cardiac white muscle disease should be attempted even though prognosis is guarded for animals with severe myocardial damage. Immediate administration of selenium and vitamin E by injection provides rapid replenishment of deficient nutrients and halts ongoing oxidative damage to surviving cardiac muscle. Injectable selenium products, typically sodium selenite or selenomethionine, should be administered according to label directions with careful attention to dosing, as selenium toxicity can occur with excessive doses. Vitamin E injection provides immediate antioxidant support. Rest and minimal handling reduce cardiac workload during the critical treatment period.

Medical management of cardiac white muscle disease beyond emergency selenium and vitamin E administration includes supportive care for heart failure if the animal is stable enough for continued treatment. Diuretic therapy with furosemide reduces pulmonary edema and improves respiratory function. Fluid therapy may be needed for dehydration but must be administered cautiously to avoid overloading the failing heart. Oxygen supplementation benefits animals in respiratory distress if equipment is available. Positive inotropic agents are not typically used in ruminant practice but theoretically could support cardiac function. Anti-inflammatory therapy may reduce ongoing muscle damage.

Treatment of concurrent skeletal muscle disease follows similar principles, with selenium and vitamin E administration forming the foundation of therapy. Animals with significant skeletal muscle involvement may be recumbent and require nursing care including turning, soft bedding, and assisted feeding if unable to stand. Pain from muscle damage may benefit from anti-inflammatory therapy. Physical therapy and assisted standing may help prevent secondary complications of recumbency in animals that survive the acute phase. Recovery from skeletal muscle disease is generally more complete than recovery from cardiac damage due to the regenerative capacity of skeletal muscle.

Supportive care for animals recovering from white muscle disease includes continued nutritional support, protection from stress, and gradual return to normal activity. Oral selenium and vitamin E supplementation continues treatment initiated parenterally and builds tissue reserves. Adequate nutrition supports tissue repair and recovery. Protection from cold, heat, and other environmental stressors reduces metabolic demands during recovery. Gradual increase in activity allows assessment of exercise tolerance as cardiac function improves. Monitoring for relapse or failure to improve guides decisions about continued treatment versus euthanasia.

Herd or flock treatment protocols should be implemented when white muscle disease is diagnosed in individual animals, as other animals in the group are likely to be similarly deficient. Injectable selenium and vitamin E should be administered to all at-risk animals in the group, particularly neonates and young stock. Dams should be supplemented to improve selenium transfer through milk. Feed and mineral supplementation should be reviewed and corrected to prevent additional cases. Testing selenium status in sample animals helps assess the extent of deficiency and guide supplementation intensity.

Treatment decisions for individual animals with white muscle disease must consider prognosis, which is substantially worse for the cardiac form than for skeletal muscle disease alone, and the welfare implications of attempted treatment versus euthanasia. Animals with severe cardiac involvement that are recumbent, severely dyspneic, and showing signs of circulatory collapse have poor prognosis and euthanasia may be the most humane option. Animals caught early with mild to moderate signs have better prognosis and warrant treatment attempts. Response within twenty-four to forty-eight hours of treatment indicates potential for recovery.

Recovery from cardiac white muscle disease is possible if treatment is initiated before severe irreversible myocardial damage occurs, but the prognosis is substantially more guarded than for the skeletal muscle form of the disease. Unlike skeletal muscle, which has significant regenerative capacity, cardiac muscle regeneration is extremely limited, and areas of severe damage are replaced by fibrous scar tissue rather than functional myocardium. Animals that survive the acute phase may have permanently reduced cardiac reserve, though mild cases can achieve functional recovery adequate for normal production life. Complete restoration of normal cardiac function is unlikely in animals with significant myocardial damage.

Post-treatment care and monitoring for animals recovering from white muscle disease includes continued selenium and vitamin E supplementation to prevent relapse and support ongoing recovery. Oral supplementation is typically continued for several weeks after acute treatment. Activity should be restricted initially and gradually increased as strength returns and exercise tolerance improves. Monitoring for respiratory distress, exercise intolerance, or other signs of cardiac compromise helps detect animals with inadequate cardiac recovery that may need management modification or culling. Serial muscle enzyme testing can track resolution of muscle damage.

Prognosis for cardiac white muscle disease depends on the severity of myocardial damage at the time of treatment initiation and the rapidity of response to therapy. Animals that respond within twenty-four to forty-eight hours with improved strength, decreased respiratory effort, and improved appetite have fair prognosis for survival, though long-term cardiac function may remain compromised. Animals that fail to respond to treatment within this timeframe or continue to deteriorate have poor prognosis. Animals found recumbent with severe respiratory distress and circulatory collapse have grave prognosis regardless of treatment. Overall survival rates for the cardiac form are substantially lower than for skeletal muscle disease.

Return to production considerations for animals recovering from white muscle disease include assessment of residual cardiac limitations and the demands of their intended use. Animals intended for breeding may function adequately if cardiac damage was mild, as breeding does not require sustained intense exercise. Growing meat animals may reach market weight if cardiac reserve is sufficient to support growth, though severely affected animals may grow poorly and should be culled. Dairy or working animals with significant cardiac compromise may not tolerate the physical demands of production. Animals with significant residual cardiac compromise should not be retained for breeding to avoid potential genetic selection for animals that survive despite inadequate selenium nutrition.

Vaccination plays no direct role in white muscle disease prevention since the condition is nutritional rather than infectious. However, maintaining overall health through appropriate vaccination programs reduces stress and metabolic demands that might precipitate clinical disease in marginally deficient animals. Clostridial vaccination is particularly important in young ruminants that are at risk for both white muscle disease and clostridial diseases. Healthy animals with adequate immune function from appropriate vaccination are better able to tolerate nutritional stress than animals fighting concurrent infections.

Biosecurity measures are not directly applicable to white muscle disease prevention as the condition is not contagious. However, general biosecurity practices that reduce disease introduction and spread decrease the additional metabolic stress of infectious disease that could precipitate white muscle disease in marginally deficient animals. Quarantine of new animals allows assessment of selenium status before introduction to the herd. Animals from selenium-adequate regions moving to deficient areas require supplementation adjustment. Reducing overall disease pressure through biosecurity supports the comprehensive health management that includes adequate nutrition.

Nutritional prevention is the cornerstone of white muscle disease control and is highly effective when properly implemented. Selenium supplementation can be provided through multiple routes including mineral mixes, injections, slow-release boluses, and selenium fertilization of pastures. Free-choice mineral supplements containing selenium at appropriate levels for the region provide ongoing supplementation for grazing animals. Injectable selenium administered to pregnant dams before parturition improves fetal selenium status and colostral transfer. Slow-release selenium boluses provide long-term supplementation for animals on deficient pastures. Vitamin E supplementation through fresh green forage, commercial supplements, or injection complements selenium programs.

Management practices for white muscle disease prevention include understanding regional selenium status, testing animals to assess adequacy of supplementation programs, and adjusting supplementation based on results. Consulting with local veterinarians and extension specialists helps identify regional deficiency patterns and appropriate supplementation strategies. Testing blood or tissue selenium levels in sample animals validates supplementation program effectiveness. Increasing supplementation for pregnant and lactating females ensures adequate transfer to offspring. Ensuring adequate vitamin E intake, particularly for animals fed stored hay or processed feeds, complements selenium programs.

Monitoring and testing protocols should include periodic assessment of selenium status in at-risk populations, particularly before breeding and before the peak risk period for offspring. Blood selenium or glutathione peroxidase activity provides direct assessment of current selenium status. Liver selenium concentration at necropsy or from biopsied animals provides information about longer-term selenium status. Feed analysis documents selenium content of the diet and identifies deficient feeds requiring supplementation. Keeping records of supplementation programs, test results, and any clinical cases allows refinement of prevention programs over time.

Daily management and monitoring for white muscle disease prevention requires attention to supplementation program compliance and early recognition of potential cases. Ensuring mineral feeders remain stocked and accessible, particularly during periods of high demand such as late pregnancy and early lactation, maintains continuous selenium intake. Observing young animals for signs of weakness, stiffness, or exercise intolerance allows early detection of clinical disease. Investigating any sudden deaths in young stock includes consideration of white muscle disease. Maintaining records of supplementation and any clinical cases supports program evaluation and improvement.

Housing and environmental management for animals at risk for white muscle disease should support overall health while ensuring consistent access to supplementation. Mineral feeders should be placed where all animals can access them without competition from dominant herdmates. Shelter from extreme weather reduces stress that might precipitate clinical disease in marginally deficient animals. Clean, dry bedding supports the health of neonates at highest risk for cardiac white muscle disease. Proper storage of feeds and supplements protects vitamin E content from degradation.

Herd health programs addressing white muscle disease should integrate selenium and vitamin E supplementation into overall nutritional management and include provisions for monitoring program effectiveness. Working with veterinarians and nutritionists ensures supplementation programs are appropriately designed for regional conditions and production demands. Including selenium status testing in routine herd health monitoring identifies inadequate supplementation before clinical disease occurs. Necropsy of animals dying from any cause includes assessment for white muscle disease lesions that might indicate subclinical deficiency in the population.

Record keeping and monitoring systems should track supplementation programs, test results, and clinical cases to support continuous improvement. Documenting selenium supplement purchases, usage rates, and program compliance helps ensure consistent implementation. Recording test results and comparing to target values identifies need for program adjustment. Maintaining records of any clinical cases including outcome of treatment provides information about program gaps. Analysis of records over time reveals trends that might indicate changing regional conditions or program drift.

Economic considerations for white muscle disease prevention must recognize that the condition is entirely preventable at modest cost, making any losses from clinical disease economically unjustified as well as representing animal welfare failures. The cost of selenium supplementation through any common route is minimal compared to the value of animals lost to white muscle disease. Even in selenium-adequate regions, marginal supplementation provides insurance against variation in feed selenium content. The return on investment for appropriate supplementation programs is extremely high when measured against potential losses from inadequate prevention.

High-risk breeds for white muscle disease are not defined by breed genetics but rather by management and geographic factors that determine selenium and vitamin E exposure. All breeds of ruminants are susceptible to nutritional deficiency when intake is inadequate. Animals born and raised in selenium-deficient geographic regions are at elevated risk regardless of breed. Young, rapidly growing animals of any breed have higher antioxidant requirements and are more susceptible than mature animals. The neonatal period represents peak risk across all breeds due to dependence on maternal transfer and limited body reserves.

Production type considerations influence white muscle disease risk based on management intensity and supplementation practices. Extensively managed animals on pasture in selenium-deficient regions without mineral supplementation face the highest risk. Intensively managed animals receiving balanced rations with appropriate trace mineral supplementation face lower risk. Organic production systems may face challenges in providing adequate selenium supplementation within organic certification requirements. Breeding animals maintained for multiple years need consistent supplementation throughout their productive lives. Growing animals destined for meat production need adequate selenium for normal development and immune function.

Species susceptibility to white muscle disease varies somewhat, with lambs often cited as most commonly affected, followed by calves and goat kids. This pattern likely reflects management differences and growth rate differences rather than inherent species susceptibility. Sheep are often raised extensively on pasture with less consistent supplementation than cattle in feedlot or dairy operations. Kids and lambs have faster growth rates relative to body size than calves, potentially increasing their antioxidant demands. All young ruminants are susceptible when nutrition is inadequate. Horses, pigs, and poultry can also develop selenium and vitamin E deficiency with species-specific manifestations.

Commonly co-occurring conditions with cardiac white muscle disease include the skeletal muscle form of white muscle disease, which often develops concurrently as the same deficiency affects multiple tissues. Stiffness, weakness, and difficulty rising from skeletal muscle involvement may be observed alongside or preceding cardiac signs. Immune dysfunction from selenium deficiency increases susceptibility to infectious diseases including pneumonia, diarrhea, and umbilical infections in the same animals at risk for white muscle disease. Ill-thrift and poor growth in subclinically deficient animals often occur in herds where clinical cases appear.

Conditions with similar presentations that must be differentiated from cardiac white muscle disease include other causes of acute death, heart failure, and weakness in young ruminants. Enterotoxemia causes peracute death but shows characteristic intestinal lesions at necropsy. Septicemia from navel ill or other infections causes weakness and death but typically shows evidence of infection including fever, joint swelling, or organ abscesses. Hypoglycemia in neonates causes weakness and collapse but responds rapidly to glucose administration. Hypothermia in cold-exposed neonates causes weakness and depression but body temperature is markedly low. Congenital heart defects cause cardiac failure but lack the characteristic white streaking of degenerative myopathy.

Complications and sequelae of white muscle disease in surviving animals include permanent cardiac compromise from myocardial scarring, chronic weakness from residual skeletal muscle damage, and increased susceptibility to other diseases from ongoing immune dysfunction until selenium status is corrected. Animals that survive cardiac involvement may have reduced cardiac reserve that limits performance under stress. Chronic ill-thrift may persist in animals that were severely deficient even after supplementation if damage was extensive. Secondary infections during the period of weakness may cause additional morbidity. Long-term reproductive performance may be impaired in animals that were severely deficient during development.